Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
| Stock | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| HOODRobinhood Markets Inc. | Meyer MalkaDirector (via Ribbit-affiliated funds) | $15.1M | Added | |||
| Wtd avg $83.45; now $82.47 (−1.2%). Ribbit Capital fund vehicles; Malka disclaims beneficial ownership beyond pecuniary interest. Part of ongoing accumulation: also bought 249K shares at $80.39 on May 28. Stake now ~3.5M shares. Buying while HOOD executives are net sellers. | ||||||
| TXOTXO Partners, L.P. | Bob R. SimpsonDirector / 10% Owner | $8.23M | Added | |||
| June 2: 230,847 units at $13.41 avg; June 3: 369,153 units at $13.91 avg. Wtd avg $13.72; now $13.44 (−2.0%). Stake raised to 16.2% of outstanding. Personal-funds buying campaign since May 21 totals ~$14.4M. 13D/A also filed. Energy-focused MLP. | ||||||
| NSPInsperity, Inc. | Paul J. SarvadiChairman / CEO | $7.93M | Added | |||
| Transaction June 3 at $34.05 wtd avg (range $33.51–$34.45); now $35.38 (+3.9%). Stock surged 4.9% on the disclosure. Repeat buyer: also bought 100K shares in May. Post-purchase direct holdings: 699,670 shares + 1.1M indirect via Our Ship LP. HR/PEO sector. | ||||||
| SMMTSummit Therapeutics Inc. | Robert W. DugganCo-CEO / Director | $1.46M | Added | |||
| Transaction June 4 at $14.60 (Nasdaq −4% day); now $14.77 (+1.2%). Indirect purchase via associated trust. Part of tri-insider cluster buy: Duggan + Zanganeh (co-CEO) + Soni (COO-CFO) all bought same day. Awaiting FDA review date for ivonescimab. | ||||||
| SMMTSummit Therapeutics Inc. | Mahkam ZanganehCo-CEO / Director | $1.46M | Added | |||
| Transaction June 4 at $14.60 (Nasdaq −4% day); now $14.77 (+1.2%). Mahkam Zanganeh Revocable Trust; post-purchase trust holds 25.8M shares. Cluster buy alongside Duggan and Soni on the same day. June 2 company 8-K had authorized affiliate purchases under ATM program. | ||||||
| LODEComstock Inc. | Pei Steven Yu-TsungDirector (via Gratia Capital) | $1.45M | Added | |||
| Three tranches June 1–3: 26,177 + 153,823 + 180,000 shares at avg ~$4.03 (range $3.93–$4.14); now $3.93 (−2.5%). Gratia Capital entity stake now ~1.89M shares. CEO DeGasperis also bought 10,682 shares separately (below threshold). Mining/energy materials company. | ||||||
| SMMTSummit Therapeutics Inc. | Manmeet Singh SoniCOO / CFO / Director | $722K | Added | |||
| Transaction June 4: 25,000 shares at $14.43 + 25,000 shares at $14.46; now $14.77 (+2.3%). Post-purchase direct holdings: 3,123,603 shares. Third SMMT insider buying on June 4 alongside both co-CEOs into the market selloff. | ||||||
Scanned EDGAR Form 4 filings filed June 5–8, 2026 (covering transactions June 1–4). 7 qualifying buys (≥ $250K, transaction type P) totalling $36.4M.
Market note: The Nasdaq fell ~4% on June 4 — its worst single-day loss since April 2025. Multiple insiders stepped in as buyers that day, most visibly at Summit Therapeutics.
Theme 1 — SMMT cluster conviction buy into the selloff. Three Summit Therapeutics insiders (both co-CEOs + COO-CFO) each executed open-market purchases on June 4, the day the Nasdaq dropped ~4%. Combined value: ~$3.64M. All three are now slightly in-the-green (+1.2–2.3%). The June 2 company 8-K authorized insider/affiliate purchases under its ATM program, but these appear to be direct open-market transactions at prevailing prices. Catalyst to watch: FDA review date for ivonescimab (VEGF/PD-1 bispecific).
Theme 2 — Repeat/conviction CEO buying: NSP and TXO. Insperity's Sarvadi and TXO's Simpson are both repeat buyers deploying personal funds in size, suggesting strong conviction in their companies' near-term prospects. Sarvadi's combined May–June buys now total ~$11.1M personal capital; Simpson's YTD buying at TXO exceeds $14M.
Theme 3 — Contrarian fintech accumulation: HOOD. Meyer Malka's Ribbit-affiliated funds have now purchased ~430,000 HOOD shares in two weeks ($35M+) while insiders and executives have been net sellers. Classic "director buying while insiders sell" divergence worth monitoring.
Sector breakdown: Biotech/Pharma (SMMT), Financial Services (NSP, HOOD), Energy/MLP (TXO), Mining/Materials (LODE).
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.